Cumberland Pharmaceuticals Takes Full Control of Talicia® U.S. Sales — Cumberland Pharmaceuticals Inc.

Event summary

Cumberland Pharmaceuticals launched a national sales promotion for Talicia® in the U.S. under a co-commercialization agreement with RedHill Biopharma.
Talicia is the only FDA-approved all-in-one treatment for H. pylori infection, now listed as a first-line option in American College of Gastroenterology guidelines.
The drug has patent protection through 2042 and eight years of U.S. market exclusivity under its Qualified Infectious Disease Product designation.
H. pylori infection affects 35% of the U.S. adult population and is a leading cause of gastric cancer, contributing to 11,000 related deaths annually in the U.S.

The big picture

Cumberland Pharmaceuticals' move to fully control Talicia's U.S. sales reflects its strategy of leveraging its commercial infrastructure to drive growth from differentiated, FDA-approved brands. The launch comes as H. pylori infection remains a significant health risk, with current therapies failing in 25-40% of patients due to high antibiotic resistance. The company's focus on strengthening prescription growth aligns with broader industry trends toward targeted treatments for rare and infectious diseases.

What we're watching

Prescription Growth: How Cumberland's sales and marketing initiatives will affect Talicia's prescription growth and patient reach.
Market Exclusivity: Whether the eight years of U.S. market exclusivity will provide a significant competitive advantage.
Antibiotic Resistance: The pace at which antibiotic resistance will impact the effectiveness of Talicia and other treatments.